Form 4 for IDYA IDEAYA Biosciences, Inc.
Accepted 2023-04-13 00:00:00 ET · period of report 2023-04-12 · accession 0001610717-23-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-13 | 2023-04-12 | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $4.31 | +11.6K | 677.9K | +2% | +$50.0K |
| D | 2023-04-13 | 2023-04-12 | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $0.00 | -11.6K | 474.5K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-12 | M | A | 11,601 | $4.31 | 677,887 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-04-12 | M | D | 11,601 | $0.00 | 474,454 | D | $4.31 · — to 2028-02-26 | 11,601 Common Stock | (F1) The shares subject to the option are fully vested and exercisable. |